Supercharged immune cells take on Hard-to-Treat cancers

NCT ID NCT06318871

First seen Feb 01, 2026 · Last updated Apr 28, 2026 · Updated 12 times

Summary

This early-phase study tests whether a new immune cell therapy, called memory-like natural killer (NK) cells, can be safely given to people with advanced kidney or bladder cancers. The NK cells are taken from the patient's blood, treated with special proteins to boost their cancer-fighting ability, and then infused back along with a low dose of IL-2, a protein that activates immune cells. The study will enroll 10 participants to first check if the treatment is feasible and safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.